Abstract
It is a not a truth universally acknowledged that pharmaceutical representatives influence physician behaviour. However, the pharmaceutical industry clearly believes they do. In fact so sure are they of this that in 2000, $4.8 billion dollars were spent in the USA on ‘detailing’, the one-on-one promotion of drugs by a representative of the company1. There is a wealth of anecdotal evidence of changes in behaviour following such marketing. This includes my own experience as a prescribing adviser for a Primary Care Trust (a UK commissioning organization with responsibility for the prescribing budget), where those primary care physicians known to be most receptive to new drugs promoted by pharmaceutical representatives are referred to as ‘the lunch bunch’. However, the detailed scientific evidence in the literature is not extensive.